The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Meissner was previously listed in April as a consultant to the RSV vaccines work group for the CDC committee, before Kennedy ...

Robert F. Kennedy Jr. faced questions from Congress about his own potential conflicts of interest during a confirmation ...

A new study from UCLA Health suggests COVID-19 vaccines may protect patients from severe kidney damage. The study found ...

Women with migraine who are planning a pregnancy or become pregnant do not need to be medication-free, according to a ...

Ng reported personal fees from Bayer, Pfizer, CytomX, Jazz Pharmaceuticals, Revolution Medicines, Agenus, Johnson & Johnson, ...

Efimosfermin is a long-acting engineered variant of FGF21 designed to have a prolonged half-life, the authors noted, and has ...

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

While Pfizer said in its petition for mass tort designation that it expected many of the dismissed plaintiffs to refile their ...